27 January 2026
Paris, 27 January
The Medicines Patent Pool (MPP) welcomes the launch of the Fifth Implementation Report of the 100 Days Mission, which highlights both continued scientific progress and growing fragility in the systems needed to deliver diagnostics, therapeutics and vaccines rapidly and equitably.
The report underscores persistent gaps in pandemic preparedness, particularly for therapeutics, alongside declining investment and fragile R&D pipelines. Recent outbreaks have reinforced the consequences of these weaknesses for timely and equitable access, especially in low- and middle-income countries (LMICs).
“As the 2025 100 Days Mission report makes clear, equity must be embedded in pandemic preparedness. This means having the know-how and manufacturing capacity in place in low- and middle-income countries before outbreaks emerge,” said Charles Gore, Executive Director, MPP. “Our work on support and technology transfer of vaccines, medicines and diagnostics, as well as platforms such as mRNA, is geared to moving countries to that stage of readiness.”
MPP welcomes the report’s focus on operationalising therapeutics development and strengthening regional capacity and joins Global Expert in Paris to discuss finging. MPP stands ready to continue working with partners to help translate preparedness commitments into real-world access.
Read full 100daymission press release here.
Access the Report
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.